556-557 / 1778
Molecular integrated risk profile PORTEC-1 and 2 cohort
•
55%
of high-intermediate risk patients reclassified to
favourable
•
15%
of high-intermediate risk patients reclassified to
unfavourable
|
|
556-557 / 1778
Molecular integrated risk profile PORTEC-1 and 2 cohort
•
55%
of high-intermediate risk patients reclassified to
favourable
•
15%
of high-intermediate risk patients reclassified to
unfavourable